PRESS RELEASES
10/2021

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting 2021

FOR IMMEDIATE RELEASE San Mateo, California, October 4, 2021– Sagimet Biosciences, a clinical-stage biotechnology company, announced today that consolidated results from its Phase 2 FASCINATE-1 trial of TVB-2640 in patients…
Read More
PRESS RELEASES
08/2021

Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today…
Read More
PRESS RELEASES
07/2021

Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat

San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology…
Read More
NASH
07/2021

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Gastroenterology
Read More
PRESS RELEASES
05/2021

Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors

San Mateo, California, May 3, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of…
Read More
PRESS RELEASES
04/2021

Sagimet to Present Phase 2 Data on Lead Candidate TVB-2640 at The International Liver Congress™ 2021 (EASL)

San Mateo, California, April 23, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that additional clinical…
Read More
Oncology
04/2021

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

EClinicalMedicine
Read More
PRESS RELEASES
03/2021

Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH

In a recent Phase 2a trial, TVB-2640 improved serum biomarkers of liver injury in patients with nonalcoholic steatohepatitis (NASH)  San Mateo, California, March 16, 2021 – Sagimet Biosciences Inc., a…
Read More
PRESS RELEASES
03/2021

Sagimet Biosciences Names Dr. Eduardo Bruno Martins as Chief Medical Officer

Dr. Martins Joins the Company to Help Advance Sagimet’s Pipeline of FASN Inhibitors  San Mateo, California, March 11, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing…
Read More
PRESS RELEASES
03/2021

FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH

– Oral FASN inhibitor ASC40 shown to meaningfully reduce liver fat with a 50% responder rate – Consistent improvement in biomarkers of liver inflammation as observed in U.S. cohort Shanghai,…
Read More